Llwytho...
Why tocilizumab could be an effective treatment for severe COVID-19?
A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Transl Med |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7154566/ https://ncbi.nlm.nih.gov/pubmed/32290839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02339-3 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|